Farrell W E, Simpson D J, Bicknell J E, Talbot A J, Bates A S, Clayton R N
Centre for Cell and Molecular Medicine, School of Postgraduate Medicine, Keele University, North Staffordshire Hospital, Stoke-on-Trent, United Kingdom.
Cancer Res. 1997 Jul 1;57(13):2703-9.
We have screened 57 cases of primary, nonfunctional, pituitary adenomas for loss of heterozygosity of markers on chromosome 9p. Using a panel of 11 microsatellite markers, we found hemizygous deletion with at least one of the markers in 18 tumors (31.5%). The frequency of loss was similar in both noninvasive (8 of 26; 31%) and invasive tumors (10 of 31; 32%), suggesting that loss on this chromosome might be an early event in pituitary tumorigenesis. Two discrete areas of loss were punctuated by a region of retention of heterozygosity between the markers D9S171 and IFNA, indicative of homozygous deletion. However, multiplex PCR analysis (MTS1 and MTS2) and the presence of a 3' untranslated region polymorphism in MTS1 suggested that neither of these tumor suppressor genes was homozygously deleted. In 6 of the 18 tumors showing LOH, sufficient DNA was also available for Southern blot analysis and, in all cases, showed retention of MTS1. Cell mixing experiments of tumor cell DNA homozygously deleted for MTS1 with DNA in which neither copy of the gene was deleted only gave rise to a signal at contamination levels greater than 30% and could discriminate homozygous and hemizygous loss. These studies support the recent findings that mechanisms other than hemi- and homozygous deletion are most likely responsible for the loss of MTS1 gene product in pituitary tumors (M. Woloschak et al., Cancer Res., 56: 2493-2486, 1996.). These data show that losses on either side of 9p21-22, both or either of which may be deleted, are involved in pituitary tumorigenesis and provide evidence for distinct suppressor gene loci, in addition to MTS1, on chromosome 9p.
我们对57例原发性无功能垂体腺瘤进行了9号染色体短臂(9p)上标记物杂合性缺失的筛查。使用一组11个微卫星标记,我们在18个肿瘤(31.5%)中发现至少一个标记物的半合子缺失。非侵袭性肿瘤(26例中的8例,31%)和侵袭性肿瘤(31例中的10例,32%)的缺失频率相似,这表明该染色体上的缺失可能是垂体肿瘤发生的早期事件。在标记物D9S171和IFNA之间存在杂合性保留区域,将两个离散的缺失区域隔开,提示纯合性缺失。然而,多重PCR分析(MTS1和MTS2)以及MTS1中3'非翻译区多态性的存在表明,这两个肿瘤抑制基因均未发生纯合性缺失。在18例显示杂合性缺失(LOH)的肿瘤中,有6例也有足够的DNA用于Southern印迹分析,并且在所有病例中均显示MTS1保留。将MTS1纯合性缺失的肿瘤细胞DNA与该基因两个拷贝均未缺失的DNA进行细胞混合实验,仅在污染水平大于30%时才产生信号,并且能够区分纯合性和半合子性缺失。这些研究支持了最近的发现,即除半合子和纯合子缺失之外的机制最有可能导致垂体肿瘤中MTS1基因产物的缺失(M. Woloschak等人,《癌症研究》,56:2493 - 2486,1996年)。这些数据表明,9p21 - 22两侧的缺失,其中任何一侧或两侧都可能被删除,参与了垂体肿瘤的发生,并为9号染色体短臂上除MTS1之外的不同抑癌基因位点提供了证据。